Literature DB >> 9257759

Treatment of murine disseminated candidiasis with L-743,872.

J R Graybill1, L K Najvar, M F Luther, A W Fothergill.   

Abstract

L-743,872 (M991), which is a pneumocandin derivative, was evaluated in a mouse model of disseminated candidiasis caused by a fluconazole-resistant isolate of Candida albicans. In immunocompetent mice M991 prolonged survival at doses as low as 0.0125 mg/kg of body weight per day. In neutropenic mice 0.05 mg/kg was the lowest effective dose. M991 is a very potent drug for treatment of disseminated candidiasis.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9257759      PMCID： PMC164003     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Cilofungin (LY121019) shows nonlinear plasma pharmacokinetics and tissue penetration in rabbits.

Authors:  J W Lee; P Kelly; J Lecciones; D Coleman; R Gordee; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Fluconazole and Candida krusei fungemia.

Authors:  D A Persons; M Laughlin; D Tanner; J Perfect; J P Gockerman; J W Hathorn
Journal:  N Engl J Med       Date:  1991-10-31       Impact factor: 91.245

3.  Efficacy of cilofungin therapy administered by continuous intravenous infusion for experimental disseminated candidiasis in rabbits.

Authors:  M S Rouse; B M Tallan; J M Steckelberg; N K Henry; W R Wilson
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

4.  Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei.

Authors:  M A Fisher; S H Shen; J Haddad; W F Tarry
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

5.  Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis.

Authors:  S Redding; J Smith; G Farinacci; M Rinaldi; A Fothergill; J Rhine-Chalberg; M Pfaller
Journal:  Clin Infect Dis       Date:  1994-02       Impact factor: 9.079

6.  Cilofungin (LY121019), an antifungal agent with specific activity against Candida albicans and Candida tropicalis.

Authors:  G S Hall; C Myles; K J Pratt; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

7.  Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis.

Authors:  J D Velez; R Allendoerfer; M Luther; M G Rinaldi; J R Graybill
Journal:  J Infect Dis       Date:  1993-08       Impact factor: 5.226

8.  Fluconazole-resistant Candida in AIDS patients. Report of two cases.

Authors:  G S Heinic; D A Stevens; D Greenspan; L A MacPhail; C L Dodd; S Stringari; W M Strull; H Hollander
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1993-12

9.  In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin.

Authors:  K Bartizal; G Abruzzo; C Trainor; D Krupa; K Nollstadt; D Schmatz; R Schwartz; M Hammond; J Balkovec; F Vanmiddlesworth
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

10.  Fluconazole treatment of Candida albicans infection in mice: does in vitro susceptibility predict in vivo response?

Authors:  J R Graybill; L K Najvar; J D Holmberg; A Correa; M F Luther
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191
View more
  19 in total

1.  Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model.

Authors:  G M González; R Tijerina; L K Najvar; R Bocanegra; M Luther; M G Rinaldi; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  What's New in Antifungals?

Authors:  John M. Valgus
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

3.  Caspofungin: the first agent available in the echinocandin class of antifungals.

Authors:  Joseph Rybowicz; Cheryle Gurk-Turner
Journal:  Proc (Bayl Univ Med Cent)       Date:  2002-01

4.  Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Andreas H Groll; Tin Sein; Robert L Schaufele; Andrea Francesconi; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

5.  Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits.

Authors:  A H Groll; B M Gullick; R Petraitiene; V Petraitis; M Candelario; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

6.  Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model.

Authors:  S Kohler; L J Wheat; P Connolly; C Schnizlein-Bick; M Durkin; M Smedema; J Goldberg; E Brizendine
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

7.  Caspofungin.

Authors:  G M Keating; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

8.  Assessment of the paradoxical effect of caspofungin in therapy of candidiasis.

Authors:  Karl V Clemons; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

9.  Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases.

Authors:  Eduardo G Arathoon; Eduardo Gotuzzo; L Miguel Noriega; Rayanne S Berman; Mark J DiNubile; Carole A Sable
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 10.  Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

Authors:  Helen W Boucher; Andreas H Groll; Christine C Chiou; Thomas J Walsh
Journal:  Drugs       Date:  2004       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.